• Explore /
  • Poster
  • / Efficacy and safety of trastuzumab deruxtecan and nivolumab as third- or later-line treatment for HER2-positive advanced gastric cancer: A single-institution retrospective study.

Efficacy and safety of trastuzumab deruxtecan and nivolumab as third- or later-line treatment for HER2-positive advanced gastric cancer: A single-institution retrospective study.

Abstract Poster

Authors

null

Keitaro Shimozaki

Department of Gastrointestinal Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan

Keitaro Shimozaki , Izuma Nakayama , Daisuke Takahari , Kengo Nagashima , Koichiro Yoshino , Koshiro Fukuda , Shota Fukuoka , Hiroki Osumi , Mariko Ogura , Takeru Wakatsuki , Akira Ooki , Eiji Shinozaki , Keisho Chin , Kensei Yamaguchi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Patient-Reported Outcomes and Real-World Evidence

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr 265)

DOI

10.1200/JCO.2024.42.3_suppl.265

Abstract #

265

Poster Bd #

C3

Abstract Disclosures

Similar Posters

First Author: Ryosuke Kumanishi

First Author: Ilya Tsimafeyeu

First Author: Dirk Schadendorf

First Author: Mariela A. Blum Murphy